HER-2/neu过表达与雄激素非依赖性前列腺癌Gleason分级和临床分期的相关性研究

目的:检测HER-2/neu基因在雄激素依赖与雄激素非依赖性前列腺癌(PCa)组织中的表达情况,推测这一基因在雄激素非依赖性PCa发生中的意义。方法:收集30例雄激素依赖性PCa标本(雄激素依赖组)和24例激素非依赖性PCa标本(雄激素非依赖组),采用免疫组化方法检测HER-2/neu基因的蛋白表达,对照临床分期、Gleason分级进行分析。结果:HER-2/neu在雄激素依赖性PCa标本中的阳性表达率为10%,在雄激素非依赖性PCa的表达为33%;Gleason分级≤7分病例中HER-2/neu阳性表达率显著低于Gleason分级>7分病例组(14.29%vs26.92%,P<0.01);临床分期>T2病例中HER-2/neu阳性表达率显著高于≤T2病例组(34.62%vs7.14%,P<0.01)。结论:HER-2/neu在雄激素非依赖性PCa标本中阳性表达率高,而且随临床分期和Gleason分级的升高其阳性表达率升高。

Relationship Between HER-2/neu Over-expression and Androgen Independent Prostate Cancer

OBJECTIVE: To detect HER-2/neu expression in prostate cancer tissues of both androgen dependent and independent groups and to evaluate the role of HER-2/neu in androgen independent prostate cancer. METHODS: Immunohistochemical assay was used in the detection of HER-2/neu in the prostate cancer samples from 30 cases of androgen dependent cancer and 24 cases of androgen independent cancer. The correlation was analyzed between HER-2/neu over-expression and the tumor's clinical stage and Gleason score. RESULTS: The rates of HER-2/neu over-expression were 10% and 33% in the androgen dependent group and the androgen independent group, significantly higher in the Gleason score >7 group and the clinical stage > T2 group than in the -7 group and the > T2 group (14.29% vs. 26.92%, 34.62% vs. 7.14%, P < 0.01). CONCLUSION: The rate of HER-2/neu over-expression is high in androgen independent prostate cancer and is correlated with the tumor stage and Gleason score.